Table I.
Characteristics of Study Population
| HIV Seropositive |
HIV Seronegative | p-value* | CT with contrast | Non-contrast CT only |
p-value† | |
|---|---|---|---|---|---|---|
| N | 618 | 383 | 759 | 242 | ||
| Age (years) | 53.2(6.5) | 55.8(7.4) | <0.001 | 53.8(7.0) | 55.3(6.7) | 0.002 |
| Race | ||||||
| Caucasian (%) | 52.6 | 66.8 | <0.001 | 57.4 | 59.9 | 0.40 |
| African-American (%) | 34.0 | 24.8 | 30.3 | 31.0 | ||
| Hispanic/Other (%) | 13.4 | 8.4 | 12.3 | 9.1 | ||
| Hypertension (%) | 50.5 | 44.3 | 0.062 | 45.4 | 56.8 | 0.003 |
| Systolic blood pressure (mm Hg) | 126.7(15.0) | 127.8(14.5) | 0.34 | 126.8(14.2) | 128.4(16.5) | 0.188 |
| Hypertension medications (%) | 35.9 | 31.2 | 0.127 | 31.1 | 43.7 | <0.001 |
| Diabetes (%) | 13.0 | 8.9 | 0.053 | 9.3 | 18.1 | <0.001 |
| Diabetes medications (%) | 8.8 | 6.6 | 0.21 | 6.5 | 12.6 | 0.003 |
| Tobacco use | ||||||
| Never smoker (%) | 25.2 | 25.2 | 0.009 | 25.2 | 25.3 | 0.63 |
| Current smoker (%) | 30.9 | 22.6 | 27.0 | 30.0 | ||
| Former smoker (%) | 43.9 | 52.2 | 47.8 | 44.7 | ||
| Smoking pack-years** | 5.6(0–22.8) | 1.8(0–21.4) | 0.024 | 4.4(0–21.4) | 4.5(0–26.9) | 0.47 |
| Body Mass Index (kg/m2) | 26.1(4.5) | 27.3(4.8) | <0.001 | 26.6(4.5) | 26.6(5.2) | 0.49 |
| Glucose (mg/dL) | 102.6(25.7) | 100.7(31.2) | 0.016 | 100.1(23.7) | 107.4(38.2) | 0.002 |
| Total Cholesterol (mg/dL) | 188.0(42.3) | 191.1(36.3) | 0.128 | 188.9(38.8) | 190.1(44.1) | 0.67 |
| LDL Cholesterol (mg/dL) | 105.3(35.2) | 112.4(32.4) | <0.001 | 109.1(34.1) | 104.4(34.7) | 0.027 |
| HDL Cholesterol (mg/dL) | 48.7(16.4) | 53.2(16.0) | <0.001 | 50.3(16.1) | 50.7(17.4) | 0.88 |
| Triglycerides (mg/dL) | 174.1(130.6) | 125.7(76.3) | <0.001 | 148.8(101.4) | 177.3(150.3) | 0.010 |
| Lipid lowering medications (%) | 35.0 | 28.5 | 0.032 | 31.8 | 34.9 | 0.37 |
| Serum Creatinine (mg/dL) | 1.1(0.5) | 1.0(0.2) | 0.034 | 1.0(0.2) | 1.3(0.8) | <0.001 |
| HIV clinical factors | 618 | 450 | 168 | |||
| Current HIV RNA undetectable, < 50 copies/mL (%) | 82.4 | 80.4 | 87.7 | 0.037 | ||
| Current HIV RNA (copies/mL)& | 723(139–24000) | 1121(138–34,100) | 602(197–7675) | 0.68 | ||
| Current CD4+ T-cell count (cells/mm3) | 601(427–766) | 602(428–773) | 599(417–757) | 0.74 | ||
| CD4+ T-cell count nadir (cells/mm3) | 244(134–332) | 254(155–339) | 216(98–318) | 0.009 | ||
| HAART experienced (%) | 96.0 | 95.3 | 97.6 | 0.199 | ||
| Protease Inhibitor use (%) | 48.7 | 47.3 | 52.4 | 0.26 | ||
| NNRTI use (%) | 47.1 | 48.2 | 44.0 | 0.36 | ||
| HAART Duration (years) | 12.5(8.7–14.1) | 12.2(8.5–14.0) | 13.1(9.6–14.4) | 0.031 | ||
| Protease Inhibitor Duration (years) | 5.1(0.4–9.6) | 4.8(0.3–8.9) | 6.0(1.4–11.0) | 0.017 | ||
| NNRTI Duration (years) | 3.8(0.6–7.9) | 3.9(0.6–7.8) | 3.5(0.6–8.0) | 0.76 | ||
| History of AIDS (%) | 14.2 | 11.1 | 22.6 | <0.001 |
Data are presented stratified by HIV serostatus for the entire cohort and then stratified by whether or not a CT with contrast was performed. Laboratory Glucose and Triglycerides results represent fasting levels. Data are reported as mean (standard deviation) or percentage. P values are unadjusted.
P value comparing seropositive and seronegative values.
P value comparing CT with contrast versus non-contrast only values.
Median (interquartile range: 25%– 75%) for non-normally distributed variables and men (SD) for normally distributed variables.
Among 107 HIV+ men (87 with contrast CT scan) with detectable current HIV RNA (>50 copies/mL) levels. HAART= highly active retroviral therapy; NNRTI= non-nucleoside reverse transcriptase inhibitors